Background. Acinetobacter baumannii is a Gram-negative, aerobic, nonmotile, non-lactose fermenting, negative oxidizing and positive catalase bacterium. This bacterium can be found in the hospital environment and becomes one of the causes of nosocomial infection, one of them being nosocomial pneumonia. Nosocomial infection due to Acinetobacter baumannii has become a global issue due to its treatment resistance. Treatment against multidrug-resistant Acinetobacter baumannii (MDRAB) has now become a challenge. Pharmacological treatment that may be taken to overcome MDRAB includes colistin, fosfomycin, tigecycline, sulbactam, rifampicin, minocycline, and others. Furthermore, carbapenem can also be utilized to counter Enterobacteriaceae despite its rising prevalence of resistance in many places in the world.
Objective. To know the effect of carbapenem-phosphomycin combination on clinical parameters (blood leukocyte, differential count, sputum leukocyte, body temperature, procalcitonin, C-reactive protein, lactate, and survival) of patient with Acinetobacter baumannii-related pneumonia.
Methods. Research was conducted using retrospective cohort (observational) method and analytical descriptive design using medical records data of Royal Taruma Hospital Jakarta from year 2011 until 2015.
Result. Carbapenem-phosphomycin combination has no significant effect (p>0.05) on the clinical parameters changes (blood leukocyte, differential count, sputum leukocyte, body temperature, procalcitonin, C-reactive protein, lactate, and survival) of patient with Acinetobacter baumannii-related pneumonia.
Conclusion. Carbapenem-phosphomycin combination has no significant effect on the clinical parameters changes of patient with Acinetobacter baumannii-related pneumonia. |